Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Baoan Ji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8971-1463; OpenAlex author ID A5016834329; NIH RePORTER profile ID 7855408. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 1)
Trials
0
Grants
3
Labs led
3
Collaborators
54
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers, 1 grant · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 grant · 2026: 1 grant

Papers 14

  1. Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.111085↗
  2. Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth. Last author DOI 10.1016/j.pan.2022.03.019↗
  3. Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo. Co-author DOI 10.1016/j.pan.2020.12.008↗
  4. Ppard Is Essential in Acceleration of Pancreatic Ductal Adenocarcinoma Development by High-Fat Diet in Mutant Kras Mice Co-author DOI 10.1101/2020.12.04.412320↗
  5. Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53. Co-author DOI 10.1038/onc.2016.461↗
  6. Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. Co-author DOI 10.1158/0008-5472.can-14-3103↗
  7. Sphingosine-1-phosphate mediates a reciprocal signaling pathway between stellate cells and cancer cells that promotes pancreatic cancer growth. Co-author DOI 10.1016/j.ajpath.2014.06.023↗
  8. Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells. Co-author DOI 10.2217/nnm.13.84↗
  9. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1053/j.gastro.2013.08.018↗
  10. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Co-author DOI 10.1136/gutjnl-2011-300544↗
  11. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. Co-author DOI 10.1158/1541-7786.mcr-12-0022↗
  12. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. Co-author DOI 10.1186/1756-8722-5-15↗
  13. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. First author DOI 10.1371/journal.pone.0042699↗
  14. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-11-0607↗

Grants 3

  1. Mechanisms of Hereditary Pancreatitis R01DK117910↗
  2. PRSS1 Mutation and Pancreatic Cancer Tumorigenesis R01CA255068↗
  3. Develop and Characterize a Novel Animal Model of Pancreatic Cancer R21CA155165↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ying Wang · 1 shared grant, 2026 · strength 1.26
  2. Craig D. Logsdon · 9 shared papers, 2011–2024 · strength 0.58
  3. Patrick Hwu · 3 shared papers, 2011–2024 · strength 0.28
  4. Ying Ma · 3 shared papers, 2011–2024 · strength 0.28
  5. Huamin Wang · 6 shared papers, 2011–2020 · strength 0.25
  6. Yan Bi · 2 shared papers, 2014–2022 · strength 0.23
  7. Huamin Wang · 1 shared paper, 2024 · strength 0.22
  8. Xiangqin Zhao · 1 shared paper, 2024 · strength 0.22
  9. Yuebo Zhang · 1 shared paper, 2022 · strength 0.19
  10. Debabrata Mukhopadhyay · 1 shared paper, 2022 · strength 0.19
  11. Haojie Huang · 2 shared papers, 2017–2021 · strength 0.17
  12. Thiruvengadam Arumugam · 3 shared papers, 2012–2021 · strength 0.17
  13. Zobeida Cruz‐Monserrate · 3 shared papers, 2012–2017 · strength 0.12
  14. Lu Zhuang · 1 shared paper, 2021 · strength 0.11
  15. Zhaoshen Li · 1 shared paper, 2021 · strength 0.11
  16. Lisi Peng · 1 shared paper, 2021 · strength 0.11
  17. Hui Jiang · 1 shared paper, 2021 · strength 0.11
  18. Daoyan Wei · 1 shared paper, 2020 · strength 0.09
  19. Yi Liu · 1 shared paper, 2020 · strength 0.09
  20. Xiaofeng Zheng · 1 shared paper, 2020 · strength 0.09
  21. Xiangsheng Zuo · 1 shared paper, 2020 · strength 0.09
  22. Imad Shureiqi · 1 shared paper, 2020 · strength 0.09
  23. Donghui Li · 1 shared paper, 2020 · strength 0.09
  24. James C. Yao · 1 shared paper, 2020 · strength 0.09
  25. Jarosław Daniluk · 2 shared papers, 2013–2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.